Comprehensive Oncology Network Evaluating Rare CNS Tumors
NCI-CONNECT aims to advance the understanding of rare adult central nervous system (CNS) cancers by establishing and fostering patient-advocacy-provider partnerships and networks to improve approaches to care and treatment.
Primary CNS cancers are tumors that start in the brain and spinal cord. They account for less than 2% of all cancers diagnosed a year in the United States, with over 130 different types. Although all primary adult CNS tumors can be considered rare, NCI-CONNECT is starting with 12 types, each with less than 2,000 people diagnosed a year.
|View NCI-CONNECT Website|
The low incident rate of these 12 tumors means patients and researchers face unique challenges. Patients struggle to find expert care and treatments. Researchers have limited resources to study the disease and develop new therapies.
NCI-CONNECT intends to address these challenges and unmet needs by connecting patients, providers, researchers and community organizations to work in partnership.
NCI-CONNECT selected rare adult CNS tumor types:
- Atypical Teratoid Rhabdoid Tumor (ATRT)
- Choroid Plexus Tumors
- Diffuse Midline Gliomas
- Gliomatosis Cerebri
- Meningioma (High Grade)
- Oligodendroglioma / Anaplastic Oligodendroglioma
- Pineal Region Tumors
- Pleomorphic Xanthroastrocytoma / Anaplastic Pleomorphic Xanthroastrocytoma
- Primitive Neuro-Ectodermal Tumors
NCI-CONNECT has a number of studies that are open for adult patients with rare central nervous system cancers. Check back as we plan to add more.
|View NCI-CONNECT Studies|
Receive the latest news in rare adult central nervous system cancer research, care, and treatment.
- Subscribe to our newsletter.
- View the NCI-CONNECTions: A Rare Brain and Spine Tumor Blog.
- Follow us on Twitter @NIHBrainTumor #NCICONNECT.
Contact us: NCICONNECT@mail.nih.gov or call (240) 760-6530
NCI-CONNECT is a program within the Rare Tumor Patient Engagement Network (RTPEN), an initiative supported by the National Cancer Moonshot. RTPEN aims to advance research and discover new treatments for rare tumors through a collaborative network of national and international institutions that will provide expertise, personalized health care and education to patients with rare tumors.
NCI-CONNECT as part of RTPEN focuses on rare central nervous system tumors and is managed at the National Institutes of Health, National Cancer Institute, Center for Cancer Research, Neuro-Oncology Branch.